Ascendis Pharma jumps as company calls $575M 2028 convertible notes for redemption
ASND•Ascendis Pharma shares are rising as investors focus on a newly announced redemption of $575 million of convertible notes due 2028, a move that can reduce future dilution. The call for redemption follows ASND stock trading above the indenture trigger threshold, and noteholders now face a convert-or-redeem decision ahead of a May 6, 2026 redemption date.
1. What’s moving the stock
Ascendis Pharma (ASND) is trading higher as the market digests a capital-structure catalyst: the company has called all $575.0 million principal amount of its 2.25% Convertible Senior Notes due 2028 for redemption on May 6, 2026. The redemption right was triggered after ASND’s share price met the indenture condition of trading above 130% of the conversion price for the required period, putting noteholders on the clock to decide between converting into stock or accepting cash redemption.
